[go: up one dir, main page]

MX2016008594A - Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol. - Google Patents

Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol.

Info

Publication number
MX2016008594A
MX2016008594A MX2016008594A MX2016008594A MX2016008594A MX 2016008594 A MX2016008594 A MX 2016008594A MX 2016008594 A MX2016008594 A MX 2016008594A MX 2016008594 A MX2016008594 A MX 2016008594A MX 2016008594 A MX2016008594 A MX 2016008594A
Authority
MX
Mexico
Prior art keywords
glycopyrronium bromide
aerosol solution
hydroxy
salt
active ingredients
Prior art date
Application number
MX2016008594A
Other languages
English (en)
Other versions
MX368835B (es
Inventor
Bonelli Sauro
Copelli Diego
Dagli Alberi Massimiliano
Usberti Francesca
Zambelli Enrico
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49886777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016008594(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2016008594A publication Critical patent/MX2016008594A/es
Publication of MX368835B publication Critical patent/MX368835B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/124Aerosols; Foams characterised by the propellant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0021Mouthpieces therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • A61M15/0068Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/007Mechanical counters
    • A61M15/0071Mechanical counters having a display or indicator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0086Inhalation chambers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/009Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22Valves or arrangement of valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22Valves or arrangement of valves
    • A61M2039/226Spindles or actuating means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/02General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0238General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Filling Or Discharging Of Gas Storage Vessels (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describe una composición en solución para aerosol para utilizarse con un inhalador presurizado de dosis medida, que comprende bromuro de glicopirronio y formoterol, o una sal del mismo o un solvato de la sal, opcionalmente en combinación con uno o más ingredientes activos adicionales, estabilizado con una cantidad seleccionada de un ácido mineral y donde la cantidad del producto de degradación N- (3-bromo) - [2-hidroxi -5- [1-hidroxi-2- [1- (4-metoxifenil) propan-2-ilamino]etil]fenil]form amida es menor que el límite de cuantificación, cuando se almacena en condiciones de envejecimiento acelerado a 25°C y 60% de humedad relativa (RH) durante 6 meses en una lata recubierta internamente por una resina que comprende un copolímero de etileno-propileno fluorado (FEP). Los uno o más ingredientes activos opcionales pueden ser corticosteroides para inhalación que se pueden seleccionar entre: dipropionato de beclometasona, budesonida o su 22R-epímero, ciclesonida, flunisolida, propionato de fluticasona, furoato de fluticasona, furoato de mometasona, etc.
MX2016008594A 2013-12-30 2014-12-23 Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol. MX368835B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199784 2013-12-30
PCT/EP2014/079259 WO2015101576A1 (en) 2013-12-30 2014-12-23 Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination

Publications (2)

Publication Number Publication Date
MX2016008594A true MX2016008594A (es) 2016-09-26
MX368835B MX368835B (es) 2019-10-18

Family

ID=49886777

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008594A MX368835B (es) 2013-12-30 2014-12-23 Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol.

Country Status (34)

Country Link
US (2) US10596113B2 (es)
EP (3) EP3089735B1 (es)
JP (2) JP6563950B2 (es)
KR (2) KR101861119B1 (es)
CN (2) CN111150728B (es)
AR (2) AR098982A1 (es)
AU (1) AU2014375301B2 (es)
BR (1) BR112016014583B1 (es)
CA (1) CA2935305C (es)
CL (1) CL2016001653A1 (es)
CY (1) CY1120668T1 (es)
DK (1) DK3089735T3 (es)
EA (1) EA033227B1 (es)
ES (1) ES2687345T3 (es)
GE (1) GEP20186855B (es)
HR (1) HRP20181551T1 (es)
HU (1) HUE039513T2 (es)
IL (1) IL246498B (es)
LT (1) LT3089735T (es)
MA (1) MA39155A1 (es)
MX (1) MX368835B (es)
MY (1) MY182861A (es)
PE (1) PE20160997A1 (es)
PH (1) PH12016501268A1 (es)
PL (1) PL3089735T3 (es)
PT (1) PT3089735T (es)
RS (1) RS57687B1 (es)
SA (1) SA516371427B1 (es)
SG (1) SG11201605311UA (es)
SI (1) SI3089735T1 (es)
TN (1) TN2016000261A1 (es)
TW (1) TWI660747B (es)
UA (1) UA117845C2 (es)
WO (1) WO2015101576A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2515855T6 (da) 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
PT2515854E (pt) 2009-12-23 2014-05-27 Chiesi Farma Spa Formulação de aerossol para dpoc
WO2011076841A2 (en) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
CA2935305C (en) * 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
TN2016000262A1 (en) 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
EP3383366B2 (en) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
PE20191043A1 (es) 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
CN107233311B (zh) * 2017-06-27 2020-12-04 长风药业股份有限公司 一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法
EP3860580A4 (en) * 2018-10-01 2022-07-20 Kindeva Drug Delivery L.P. FORMULATION AND AEROSOL CARTRIDGES, INHALATORS AND THE LIKE CONTAINING THE FORMULATION
WO2020084549A1 (en) * 2018-10-25 2020-04-30 Glenmark Specialty S.A. Nebulization composition comprising glycopyrrolate and formoterol
US20220241524A1 (en) * 2019-07-12 2022-08-04 Kindeva Drug Delivery L.P. Aerosol formulation, canister, and inhaler containing the formulation, and method of use
KR102835735B1 (ko) 2019-12-02 2025-07-21 키에시 파르마슈티시 엣스. 피. 에이. 가압 정량 흡입기를 위한 스테인리스 스틸 캔
PE20221867A1 (es) 2020-01-28 2022-12-02 Chiesi Farm Spa Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada
AU2021223587A1 (en) 2020-02-20 2022-09-29 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
CN115989032A (zh) * 2020-07-31 2023-04-18 化学研究有限公司 用于吸入施用的组合疗法
CN112051346A (zh) * 2020-09-24 2020-12-08 珠海瑞思普利生物制药有限公司 一种同时测定茚达特罗和格隆溴铵含量的hplc方法
JP2023546025A (ja) 2020-10-09 2023-11-01 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧定量吸入器のための医薬製剤
WO2023117985A1 (en) * 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
CN116338014A (zh) * 2021-12-23 2023-06-27 上海医药工业研究院有限公司 一种吸入用药物组合物的组分分离检测方法
CA3257044A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. PHARMACEUTICAL FORMULATION FOR PRESSURIZED DOSING AEROSOL
CN119255820A (zh) 2022-05-27 2025-01-03 奇斯药制品公司 用于加压定量吸入器的药物制剂
CN119630425A (zh) 2022-05-27 2025-03-14 奇斯药制品公司 用于加压定量吸入器的药物制剂
CN117679423A (zh) 2022-09-05 2024-03-12 立生医药(苏州)有限公司 预防或治疗呼吸系统疾病的吸入用药物组合物
WO2025179179A1 (en) * 2024-02-23 2025-08-28 Astrazeneca Ab Triple combination therapy for copd
WO2026006658A1 (en) 2024-06-27 2026-01-02 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
DK1102579T3 (da) 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
UA73986C2 (uk) 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
EP1241113A1 (en) * 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
US20040126325A1 (en) * 2002-03-12 2004-07-01 David Lewis Medicinal aerosol solution formulation products with improved chemical stability
DK1713473T3 (da) 2004-02-06 2013-06-17 Meda Pharma Gmbh & Co Kg Kombination af anticholinergika og glucocorticoider til langtidsbehandling af astma og COPD
CA2550841C (en) 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
UA88894C2 (ru) * 2004-02-27 2009-12-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Стабильные фармацевтические композиции в виде растворов для ингаляторов с дозатором, которые находятся под давлением
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
ATE404185T1 (de) * 2004-05-13 2008-08-15 Chiesi Farma Spa Medizinische aerosolformulierungen mit verbesserter chemischer stabilität
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1879620A2 (en) 2005-03-30 2008-01-23 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP2201934A1 (en) * 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
CA2764867C (en) * 2009-06-09 2016-05-17 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
PT2515854E (pt) 2009-12-23 2014-05-27 Chiesi Farma Spa Formulação de aerossol para dpoc
WO2011076841A2 (en) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
DK2515855T6 (da) * 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
CN102695496B (zh) 2009-12-23 2014-10-01 奇斯药制品公司 用于copd的气雾剂制剂
BR112013005283A2 (pt) 2010-09-06 2019-09-24 Chiesi Farm Spa atuador de inalador dosimetrado, de inalador dosimetrado e uso de um atuador
PH12013502270A1 (en) * 2011-05-17 2014-01-27 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of two or more active agents
BR112015002757A2 (pt) 2012-08-29 2017-07-04 Chiesi Farm Spa acionador para dispositivo inalador de aerossol, objeto em forma cilíndrica oca, inalador, acionador de inalador dosimétrico, kit e uso de um acionador
TN2016000262A1 (en) * 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
CA2935305C (en) * 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination

Also Published As

Publication number Publication date
JP6563950B2 (ja) 2019-08-21
PH12016501268B1 (en) 2016-08-15
UA117845C2 (uk) 2018-10-10
MA39155A1 (fr) 2017-04-28
KR101861117B1 (ko) 2018-05-28
TN2016000261A1 (en) 2017-10-06
MX368835B (es) 2019-10-18
CN105848641A (zh) 2016-08-10
CY1120668T1 (el) 2019-12-11
HK1225313A1 (zh) 2017-09-08
IL246498B (en) 2020-05-31
CN111150728B (zh) 2024-02-06
US20160303045A1 (en) 2016-10-20
JP2019206557A (ja) 2019-12-05
AU2014375301B2 (en) 2020-03-26
PH12016501268A1 (en) 2016-08-15
SG11201605311UA (en) 2016-07-28
CN111150728A (zh) 2020-05-15
KR101861119B1 (ko) 2018-05-28
HUE039513T2 (hu) 2019-01-28
SA516371427B1 (ar) 2018-12-24
BR112016014583A2 (es) 2017-08-08
EP3566694A1 (en) 2019-11-13
TW201609185A (zh) 2016-03-16
EP3384898A1 (en) 2018-10-10
KR20180032660A (ko) 2018-03-30
HRP20181551T1 (hr) 2018-11-30
CA2935305A1 (en) 2015-07-09
GEAP201814191A (en) 2018-01-25
US10617638B2 (en) 2020-04-14
AU2014375301A1 (en) 2016-07-14
AR130239A2 (es) 2024-11-20
GEP20186855B (en) 2018-05-25
DK3089735T3 (en) 2018-09-17
CA2935305C (en) 2022-07-12
NZ721642A (en) 2021-02-26
EP3089735B1 (en) 2018-07-11
IL246498A0 (en) 2016-08-31
EP3089735A1 (en) 2016-11-09
AR098982A1 (es) 2016-06-22
US10596113B2 (en) 2020-03-24
CL2016001653A1 (es) 2017-08-25
ES2687345T3 (es) 2018-10-24
JP6823118B2 (ja) 2021-01-27
PE20160997A1 (es) 2016-10-14
TWI660747B (zh) 2019-06-01
PT3089735T (pt) 2018-10-19
MY182861A (en) 2021-02-05
JP2017507169A (ja) 2017-03-16
RS57687B1 (sr) 2018-11-30
LT3089735T (lt) 2018-09-10
EA201691126A1 (ru) 2016-12-30
BR112016014583B1 (pt) 2022-12-20
CN105848641B (zh) 2021-07-09
WO2015101576A1 (en) 2015-07-09
EA033227B1 (ru) 2019-09-30
US20150182450A1 (en) 2015-07-02
SI3089735T1 (sl) 2018-10-30
PL3089735T3 (pl) 2018-12-31
KR20160104041A (ko) 2016-09-02

Similar Documents

Publication Publication Date Title
MX2016008594A (es) Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol.
MX2016008591A (es) Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol.
BR112022014228A2 (pt) Inaladores pressurizados de dose calibrada compreendendo uma formulação farmacêutica tamponada
AR081540A1 (es) Proceso para proveer particulas con cargas electroestaticas reducidas
MX2021009476A (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
EA201290375A1 (ru) Комбинированная терапия copd
CO2022012207A2 (es) Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
CO2022007719A2 (es) Lata de acero inoxidable para inhaladores dosificadores presurizados
TH171992A (th) องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล
TH171993A (th) องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล
ZA202108150B (en) An inhalable fixed dose powder composition comprising glycopyrronium, formoterol and fluticasone propionate
AR085443A1 (es) Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero
TR201714893A1 (tr) Beta-2 Agonisti ve Kortikosteroid içeren kuru toz bileşimi.

Legal Events

Date Code Title Description
FG Grant or registration